Mono- or dual-therapy in bloodstream infections? That is the question
Monday, July 12, 2021
2. Bacterial infection & disease, 1-hour Oral Session
•
S52
•
1:15 PM
>
2:15 PM
•
Mono- or dual-therapy in bloodstream infections? That is the question
•
2. Bacterial infection
1:15 PM
•
1133
•
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC β-lactamase producing <i>Enterobacter</i> spp., <i>Citrobacter freundii, Morganella morganii, Providencia</i> spp., or <i>Serratia marcescens</i>: a pilot multi-centre randomised controlled trial (MERINO-2)
>
A.
Adam
STEWART (Brisbane)
1:25 PM
•
1432
•
ß-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to <em>Pseudomonas aeruginosa</em>: a meta-analysis
>
L.
Lorenzo
ONORATO (Naples (Na))
1:35 PM
•
862
•
Ceftolozane/tazobactam for the treatment of <em>Pseudomonas aeruginosa</em> bloodstream infection in neutropaenic haematologic patients: a case-control study (ZENITH study)
>
A.
Alba
BERGAS FARRÉS (Hospitalet Del Llobregat)
1:45 PM
•
843
•
Effect of therapeutic drug monitoring-based dose optimisation of piperacillin-tazobactam (TZP) on sepsis-related organ dysfunction in patients with sepsis: a randomised clinical trial
>
S.
Stefan
HAGEL (Jena)
1:55 PM
•
2522
•
Clinical outcomes with empiric antimicrobial therapy of patients with polymicrobial <em>Escherichia coli</em> or <em>Klebsiella pneumoniae</em> bloodstream infections
>
A.
Aaron
HAMBY (Charleston)
2:05 PM
•
INT69
•
Q&A/Discussion
|